Compare VERU & AERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | AERT |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 39.7M |
| IPO Year | 1996 | 2021 |
| Metric | VERU | AERT |
|---|---|---|
| Price | $2.63 | $6.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 278.7K | 10.3K |
| Earning Date | 05-12-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 110.87 |
| EPS | N/A | ★ 0.27 |
| Revenue | $16,296,958.00 | ★ $70,014,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $26.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.05 | $0.26 |
| 52 Week High | $7.33 | $7.45 |
| Indicator | VERU | AERT |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 56.76 |
| Support Level | $2.12 | $6.11 |
| Resistance Level | $2.67 | $7.30 |
| Average True Range (ATR) | 0.14 | 0.44 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 65.75 | 73.91 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs. It has more than 40 clients spanning across industry segments.